ABSTRACT
HSCT in autoimmune diseases has evolved gradually since the mid-1990s. As per other areas of HSCT and cellular therapy practice, data from many patients have been captured in the established major transplant registries; the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). From an early stage, this enabled assessment of activity across the transplant community, with evaluation of safety and benefit through analysis of aggregated data. As the field has evolved, data collected in international registries has formed the basis for larger, more sophisticated analyses across the main autoimmune disease indications, whilst smaller numbers of sporadic cases in the rare indications have been brought together for meaningful summary statements. Registry data have provided the basis for prospective clinical studies as well as guidelines and recommendations for evidence-based practice. This chapter summarizes the global nature of the EBMT and CIBMTR registries and their roles across all aspects of HSCT and cellular therapy practice, and then discusses the current status and their publication outputs in relation to autoimmune diseases.
